National Roller Derby League

Blend On the Go, Wherever Life Takes You with magic bullet®'s New Portable Blender

Retrieved on: 
Tuesday, September 26, 2023
Magic, National Roller Derby League, Target, Ice, Roller Skates, Amazon (company), Tritan, LOS, Entertainment

LOS ANGELES, Sept. 26, 2023 /PRNewswire/ -- Get ready to embark on a flavor-filled adventure with the all-new magic bullet® Portable Blender. This innovative and versatile appliance is designed to empower the creation of delicious blends anywhere, any time.

Key Points: 
  • Equipped with cutting-edge technology, the magic bullet® Portable Blender mixes all your favorite blended creations, wherever you happen to be.
  • LOS ANGELES, Sept. 26, 2023 /PRNewswire/ -- Get ready to embark on a flavor-filled adventure with the all-new magic bullet® Portable Blender .
  • The magic bullet® Portable Blender redefines the blending experience by delivering durability, efficiency, and affordability in a compact, portable package.
  • Customers can purchase the magic bullet® Portable Blender at themagicbullet.com , Target, Amazon.com, and other favorite retailer websites.

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List

Retrieved on: 
Tuesday, December 29, 2020
Finance, Financial markets, Money, National Healthcare Security Administration, State Council of the People's Republic of China, National Roller Derby League, Hong Kong Exchanges and Clearing, Reimbursement, Zai

SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA has been included in the updated National Reimbursement Drug List (NRDL) released by Chinas National Healthcare Security Administration (NHSA).

Key Points: 
  • SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA has been included in the updated National Reimbursement Drug List (NRDL) released by Chinas National Healthcare Security Administration (NHSA).
  • The inclusion of our first NMPA-approved medicine, ZEJULA, in the NRDL is an important step in achieving that mission.
  • NHSA reimbursement will help make ZEJULA affordable to many patients in need across China, said William Liang, Chief Commercial Offer.
  • Zai Lab also conducted a Phase I pharmacokinetic (PK) study of ZEJULA in Chinese patients with ovarian cancer.

FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List

Retrieved on: 
Monday, December 2, 2019
Companies, Acetic acids, Isoquinolines, Roxadustat, National Roller Derby League, AstraZeneca, National Healthcare Security Administration, Reimbursement, Economy, Business

SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by Chinas National Healthcare Security Administration (NHSA).

Key Points: 
  • SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by Chinas National Healthcare Security Administration (NHSA).
  • Inclusion on the NRDL is a significant milestone and inflection point for the growth trajectory for roxadustat, as reimbursement provides affordability and access for patients on a national basis, said Jim Schoeneck, Interim CEO, FibroGen.
  • FibroGen and AstraZeneca will work diligently with provincial governments and hospitals to make this new treatment option available to patients.
  • Roxadustat was among 97 drugs that were included on the updated NRDL list through negotiations, the highest number in history.

Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China

Retrieved on: 
Thursday, November 28, 2019
National Roller Derby League

Elunate is Chi-Meds first novel oncology drug commercially launched in China, commented Mr. Christian Hogg, Chief Executive Officer of Chi-Med.

Key Points: 
  • Elunate is Chi-Meds first novel oncology drug commercially launched in China, commented Mr. Christian Hogg, Chief Executive Officer of Chi-Med.
  • The inclusion in the NRDL is a very important step forward to broaden availability and patient access to Elunate across China.
  • In recent years, the government in China has placed great importance on improving the public affordability of drug use.
  • In this 2019 update, the NHSA has added and renewed over 20 Category B oncology drugs to the NRDL, including Elunate.